News - This highly innovative genomic centre in pediatrics located at Sainte-Justine UHC, the largest mother-child university hospital centre in Canada, will contribute to the development of new solutions to diagnostic challenges in children with genetic diseases. The initiative will transform the quality of care made available to young patients and improve prevention efforts from early childhood. This Canadian first represents a tremendous source of hope for sick children and their families.
News - To encourage the development of technological businesses in Québec, the Anges Québec private investors network has entered into a privileged partnership agreement with Valeo Management, MSBi Valorisation, SOVAR and Univalor, technology transfer and commercialization companies derived from university research in Québec. This agreement will favour the sharing of expertise and the pooling of resources and financial and business networks to support innovative seed companies that commercialize technologies derived from university research.
News - Merck Canada announced yesterday the allocation of a total of $16 million in grants to Quebec’s four faculties of medicine. McGill, along with Université de Montréal, Université de Sherbrooke and Université Laval will each receive $4 M to support health research with a translational component conducted in areas of unmet medical need.
News - Researchers from Université Laval’s Faculty of Medicine and CHU de Québec have shown that it is possible to treat venous ulcers unresponsive to conventional treatment with wound dressings made from human skin grown in vitro. A study published recently in the journal Advances in Skin and Wound Care demonstrates how this approach was successfully used to treat venous lower-extremity ulcers in patients who had been chronically suffering from such wounds.
News - Today and tomorrow (Oct. 2 - 3), the main stakeholders of the pharmaceutical and biopharmaceutical industry, venture capital companies, academic researchers and government representative will be brought together for the 19th edition of BioContact Quebec. During two days, they will have the opportunity to develop new partnerships. "This is an exceptional opportunity for the pharmaceutical and biopharmaceutical industry, which has been experiencing major changes in the recent years", explained Dr. Martin Godbout, president of the event.
News - Aeterna Zentaris announces the successful completion of its previously announced agreements with various partners and licensees with respect to the manufacturing rights and obligations for its Cetrotide® product. The principal outcome of such agreements is the transfer of manufacturing rights and the grant of a manufacturing license for Cetrotide® to a subsidiary of Merck KGaA of Darmstadt, Germany, in all jurisdictions. Under the terms of these agreements, Aeterna Zentaris will receive a one-time payment of €2.5 million, or approximately $3.3 million. Cetrotide® (cetrorelix acetate for injection) is used to regulate hormone responses in women undergoing infertility treatment. Merck Serono currently markets Cetrotide®worldwide.
News - (Press release in french only) The first work meeting of Alliance santé Québec (Québec City Health Alliance) took place on October 1st, at Domaine Cataraqui in Qubec City. This new entity brings together key players from the greater Quebec City region working in in research and innovation in various health-related fields. Acting as as a forum for discussion and action, the group’s primary objective is to increase and optimize research efforts for the health of individuals and populations.
News - The 19th edition of BioContact Quebec, the international symposium on bio-pharmaceutical partnerships, will take place on October 2nd and 3rd. For two days, representatives of almost 100 pharmaceutical and bio-pharmaceutical companies from Canada, the United States and Europe as well as some 150 participants from universities, consulting firms, venture capital companies and government representatives will be on site to exchange and develop business partnerships.
News - Mitsubishi Tanabe Pharma Corporation and Medicago announced the completion of the previously announced acquisition of Medicago Inc. by MTPC. On September 18, 2013, 9284-9686 Québec Inc.,a subsidiary of MTPC, acquired all of the outstanding common shares of Medicago, other than the common shares currently held by MTPC and Philip Morris Investments B.V. an affiliate of Philip Morris International Inc., pursuant to the terms of an arrangement agreement made as of July 12, 2013. As a result, Medicago has become jointly owned by MTPC (60%) and PMI (40%).
News - As part of its mandate to support Canadian entrepreneurs, BDC Venture Capital announced today it has allocated $135 million in new capital to direct venture investments in innovative healthcare companies. That brings its total direct commitment to the sector to $270 million. Recognizing a massive and growing market opportunity, the BDC Venture Capital Healthcare Fund will broaden its investment strategy and invest in technology, products and services that aim to dramatically improve global healthcare productivity, efficiency and patient outcomes.